CAS 2230911-59-6

INCB086550

CAS: 2230911-59-6

INCB086550

Formel: C₄₁H₃₉N₇O₄

Reinheit: ≥98%

Molekulargewicht: 693.79

Ref: 54-BUP00724

(3R)-1-[[7-Cyano-2-[3′-[[3-[[(3R)-3-hydroxy-1-pyrrolidinyl]methyl]-1,7-naphthyridin-8-yl]amino]-2,2′-dimethyl[1,1′-biphenyl]-3-yl]-5-benzoxazolyl]methyl]-3-pyrrolidinecarboxylic acid

CAS: 2230911-59-6

Formel: C₄₁H₃₉N₇O₄

Reinheit: 98%

Farbe und Form: Solid

Molekulargewicht: 693.7929

Ref: IN-DA01V7DK

INCB086550

CAS: 2230911-59-6

(R)-1-((7-Cyano-2-(3'-((3-(((R)-3-hydroxypyrrolidin-1-yl)methyl)-1,7-naphthyridin-8-yl)amino)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid

Formel: C₄₁H₃₉N₇O₄

Reinheit: 98%

Molekulargewicht: 693.79

Ref: IN-DG01486246

Pd-1/Pd-L1-in-8

CAS: 2230911-59-6

Pd-1/Pd-L1-in-8 is an inhibitor that targets the PD-1/PD-L1 pathway, which is involved in regulating immune responses. This inhibitor has been developed by Chinese researchers and has shown promising results in preclinical studies as a potential treatment for various types of cancer. Pd-1/Pd-L1-in-8 is a kinase inhibitor that works by blocking the activity of specific kinases involved in cancer cell growth and survival. It induces apoptosis, programmed cell death, in cancer cells and shows potent anticancer activity. The analog of this medicinal compound has been isolated from human urine and demonstrates significant potential as an anticancer drug.

Formel: C₄₁H₃₉N₇O₄

Reinheit: Min. 95%

Molekulargewicht: 693.8 g/mol

Ref: 3D-FPD91159

INCB086550

CAS: 2230911-59-6

INCB086550 (PD-1/PD-L1-IN-8) (example 24) is a PD-1/PD-L1 inhibitor, with an IC50 <= 10 nM.

Formel: C₄₁H₃₉N₇O₄

Reinheit: 98.49%

Farbe und Form: Solid

Molekulargewicht: 693.79

Ref: TM-T36899